What's Happening?
Hernando Salcedo, an 83-year-old grandfather, was diagnosed with Stage III pancreatic cancer in May 2025. After experiencing severe side effects from traditional chemotherapy, Salcedo was presented as a candidate for a clinical trial at the Miami Cancer
Institute. The trial involved a new chemotherapy delivery device from RenovoRX, designed to target the tumor more precisely and reduce side effects. The RenovoCath system uses a catheter to deliver chemotherapy directly to the tumor, minimizing exposure to the rest of the body. This method has shown to reduce adverse effects and increase survival rates. Salcedo participated in the trial and reported significant improvements in his quality of life, experiencing fewer side effects compared to traditional chemotherapy.
Why It's Important?
This clinical trial represents a significant advancement in the treatment of pancreatic cancer, a disease known for its poor prognosis and limited treatment options. The RenovoCath system's ability to deliver chemotherapy more precisely could revolutionize how pancreatic cancer is treated, potentially extending the lives of patients while maintaining their quality of life. The trial's success could lead to broader adoption of this method, offering hope to many patients who previously had limited options. The development also highlights the importance of clinical trials in advancing cancer treatment and the potential for innovative medical devices to improve patient outcomes.
What's Next?
The RenovoCath system has been cleared by the FDA, and further research is ongoing. The final trial data for its use in Stage III pancreatic cancer is expected to be published in late 2027. If the results continue to be positive, this could lead to wider implementation of the device in clinical settings. The success of this trial may also encourage further research into similar targeted delivery systems for other types of cancer, potentially transforming cancer treatment protocols.
